Michael Graham - Benitec Biopharma Founding Scientist and Head of Discovery
| BNTC Stock | USD 10.49 0.29 2.84% |
Executive
Michael Graham is Founding Scientist and Head of Discovery of Benitec Biopharma Ltd since 2012.
| Tenure | 12 years |
| Address | 3940 Trust Way, Hayward, CA, United States, 94545 |
| Phone | 510 780 0819 |
| Web | https://benitec.com |
Benitec Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.496) % which means that it has lost $0.496 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9168) %, meaning that it created substantial loss on money invested by shareholders. Benitec Biopharma's management efficiency ratios could be used to measure how well Benitec Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.44. In addition to that, Return On Capital Employed is expected to decline to -0.5. At present, Benitec Biopharma's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 54.3 M, whereas Other Current Assets are forecasted to decline to about 501.1 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Anthony Price | Bio Path Holdings | N/A | |
| Charles Garner | Aileron Therapeutics | 48 | |
| MBA MBA | Bio Path Holdings | N/A | |
| Steven CPA | NextCure | 61 | |
| Theresa Lowry | Zura Bio Limited | 50 | |
| Kiran MBBS | Zura Bio Limited | 51 | |
| Melda Oconnell | ZyVersa Therapeutics | N/A | |
| Deborah Ascheim | Capricor Therapeutics | 59 | |
| Stacy Rollinger | NextCure | N/A | |
| MD FACC | ZyVersa Therapeutics | 74 | |
| MBA Ashizawa | Bio Path Holdings | N/A | |
| Kristi Elliott | Capricor Therapeutics | N/A | |
| Verender Badial | Zura Bio Limited | 52 | |
| David Brady | Zura Bio Limited | N/A | |
| Udayan MD | NextCure | N/A | |
| Gary Whale | Zura Bio Limited | 50 | |
| Kevin Shaw | NextCure | 49 | |
| Kimberly Davis | Zura Bio Limited | 56 | |
| Sebastien Maloveste | NextCure | N/A | |
| MD FACC | Capricor Therapeutics | 68 | |
| Michael Howell | Zura Bio Limited | 47 | |
Management Performance
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.5 |
Benitec Biopharma Leadership Team
Elected by the shareholders, the Benitec Biopharma's board of directors comprises two types of representatives: Benitec Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Benitec. The board's role is to monitor Benitec Biopharma's management team and ensure that shareholders' interests are well served. Benitec Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Benitec Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Graham, Founding Scientist and Head of Discovery | ||
| Bryan Dulhunty, Chief Officer | ||
| Claudia Kloth, Senior Manufacturing | ||
| Craig Lewis, Chief Adviser |
Benitec Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Benitec Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.5 | ||||
| Current Valuation | 169.18 M | ||||
| Shares Outstanding | 19.82 M | ||||
| Shares Owned By Insiders | 4.38 % | ||||
| Shares Owned By Institutions | 46.12 % | ||||
| Number Of Shares Shorted | 56.89 K | ||||
| Price To Earning | (5.10) X | ||||
| Price To Book | 3.69 X | ||||
| Price To Sales | 2,770 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Benitec Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Benitec Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Benitec Biopharma Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Benitec Biopharma Ltd Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Benitec Biopharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Benitec Biopharma. If investors know Benitec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Benitec Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.51) | Revenue Per Share 0.003 | Quarterly Revenue Growth 0.125 | Return On Assets (0.50) | Return On Equity (0.92) |
The market value of Benitec Biopharma is measured differently than its book value, which is the value of Benitec that is recorded on the company's balance sheet. Investors also form their own opinion of Benitec Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Benitec Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Benitec Biopharma's market value can be influenced by many factors that don't directly affect Benitec Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Benitec Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Benitec Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Benitec Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.